Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe tumor immune cells in bone cancer patients treated with mifamurtide

NCT ID NCT03737435

Knowledge-focused Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study examined stored tumor samples from 80 people with localized osteosarcoma who received chemotherapy with or without the drug mifamurtide. Researchers analyzed the immune cells and genes inside the tumors to see how the tumor environment relates to patient survival. The goal is to better understand why some patients respond better to treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mifamurtide
What this could lead to
If successful, this could help doctors understand which patients with osteosarcoma might benefit most from adding mifamurtide to chemotherapy.
What could go wrong
This is a retrospective biological study, not a treatment trial. It only looks at stored tumor samples, so it cannot prove that mifamurtide works better or causes harm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

80 people

The number who actually took part.

Started

Dec 2018

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

male and female without limit of age

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with primary localized osteosarcoma who received chemotherapy +/- mifamurtide according to ISG-OS2/GEIS-33 trials, 2. Paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the biological analysis 3. Written informed consent prior to any study-specific analysis and/or data collection Exclusion Criteria: 1\) Patients with diagnosis different from osteosarcoma \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized osteosarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

localized osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Localized osteosarcoma

Contacts and locations

Locations

  • SSD Chemioterapia dei tumori dell'apparato locomotore

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.